Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
‘We’re saving lives’: naloxone pilot prevents three deaths per day
Pharmacists discuss the impressive results of the Take Home Naloxone Pilot and why subsidised access to the medicine is a must going forward.
Bridget Totterman is making her own path
Meet Bridget Totterman, PSA's 2020 Queensland Pharmacist of the Year.
Allergic rhinitis and COVID-19: advice for pharmacists
At a time when it is vital to identify and treat individuals infected with the COVID-19 virus, it is also important to recognise and manage the symptoms of allergic rhinitis.
Aggression ramps up in pharmacies as fear increases
Aggressive consumers wanting quantities of ‘just in case’ medicines amid COVID-19 panic has added considerably to workplace stress.
Preparing for the NSW pharmacy prescribing pilot
From 15 May 2023, women in NSW can access treatment for uncomplicated urinary tract infections through the pharmacy prescribing pilot.
How up to date is your pharmacy practice knowledge?
It’s been another big year for pharmacy practice. Before we wrap up 2023, it’s time to put your knowledge to the test.
